<DOC>
	<DOC>NCT01030926</DOC>
	<brief_summary>This trial was conducted in Europe. The aim of this clinical trial was to look into the concentration of NN1250 (insulin degludec/insulin 454) in the blood after one injection of NN1250 in children, adolescents and adults with type 1 diabetes.</brief_summary>
	<brief_title>A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male or female aged 665 years (both inclusive) Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months Body mass index for children: 15.020.0 kg/m^2 (both inclusive), for adolescents: 18.028.0 kg/m^2 (both inclusive) and for adults maximum 30.0 kg/m^2 Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening Not able or willing to refrain from smoking during the inpatient period Female of childbearing potential who is pregnant, breastfeeding or intends to become pregnant or is not using adequate contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>